For instance, gefitinib, one of the EGFR inhibitors, was initially investigated in a clinical trial for patients with advanced non-small cell lung cancer regardless of EGFR mutation status, showing a response rate of 9–12%62. Here, EGFR is linked to non-small cell lung carcinoma.